StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $16.64 | $16.52 | -0.72% | 0.4M |
| 05-12 | $16.53 | $16.48 | -0.30% | 0.3M |
| 05-13 | $16.36 | $16.67 | +1.89% | 0.4M |
| 05-14 | $16.79 | $16.51 | -1.67% | 0.4M |
| 05-15 | $16.49 | $16.22 | -1.64% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Annual 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $17.70M | $107.46M | $19.99M | $26.20M |
Operating Income | $-9.48M | $-3.60M | $-6.46M | $-2.73M |
Net Income | $-4.93M | $105.89M | $3.62M | $54.84M |
EPS (Diluted) | $-0.10 | $2.06 | $0.07 | $1.08 |
Total Assets | $472.31M | $485.57M | $415.46M | $426.04M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $288.10M | $167.81M | $174.77M | $281.93M |
Free Cash Flow OCF − CapEx | Not available | $238.50M | $244.57M | $251.08M |
Shares Outstanding | 51.52M | 51.07M | 50.67M | 50.36M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.